Overview
This book represents the synthesis of many current cancer theories, which combined, offers a novel and innovative approach in the diagnosis, prevention, and treatment of cancer. It introduces a new and different paradigm in the diagnosis, prevention, and treatment of cancer, by taking into account the organism as a whole, which is very different from the current cellular/tissular approach toward cancer. In this new paradigm, cancer involves dynamic interactions with the entire body and its internal milieu. Focusing on these interactions will permit pre-clinical cancer diagnosis and novel treatment approaches. This onco-holobiont model integrates most of the current malignant process models and it is intended for the use of practitioners/clinicians, cancer researchers, and students with a particular interest in cancer. The goal of this book is to inspire scientists to go beyond the current methods in the treatment of cancer and discover new paradigms.
Full Product Details
Author: Doru Paul
Publisher: Springer Nature Switzerland AG
Imprint: Springer Nature Switzerland AG
ISBN: 9783032088079
ISBN 10: 3032088070
Pages: 342
Publication Date: 27 December 2025
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Forthcoming
Availability: Not yet available
This item is yet to be released. You can pre-order this item and we will dispatch it to you upon its release.
Author Information
Doru Paul M.D., PhD Associate Professor of Clinical Medicine Weill Cornell Medical College New York-Presbyterian Hospital Department of Medicine Division of Hematology/Oncology New York, NY Dr. Paul received his MD from the Carol Davila Faculty of Medicine in Bucharest, Romania and his PhD from the Faculty of Medicine in Craiova, Romania. He also got diplomas in Clinical Oncology, Chronobiology and Biology of Aging from Paris, France and he completed his training in Internal Medicine, Hematology and Medical Oncology in New York. Dr. Paul is an experienced clinician with more than ten thousand cancer patients treated until now and with a strong background in basic and translational research. He has designed and conducted several investigator initiated studies and initiated three FDA approved investigational new drug studies including the first in-man pilot study that uses [18F] Fluorodeoxyglucose (FDG) for the targeted treatment of cancer. Since 2015, he has been working on a novel cancer model [see, for example “The systemic hallmarks of cancer” (2020) and “Cancer as a form of life: Musings of the cancer and evolution symposium” (2021). He is also the senior oncology editor of the verywellhealth.com website and the editor-in-chief of the Journal of Medical and Radiation Oncology.
